Search

A female patient T., 67 years, had a 30-year anamnesis of heart failure, HF (NYHA Functional Class III) with normal left ventricular ejection fraction and Stage II arterial hypertension. After thyroidectomy in 1987, the patient received L-thyroxin. The patient also received long-term standard antihypertensive therapy and HF treatment. Due to ineffective therapy and increased dyspnoea, radionuclide ventriculography was performed, suggesting restrictive cardiomyopathy. Intracoronary injection of autologous bone marrow stem cells was performed. Four months later, an improvement in clinical status (NYHA FC I) was associated with improved diastolic function at ventriculography. Immunological analysis confirmed a virus infection.

Clinical effectiveness of a new Russian antiarrhythmic agent nibentan, Class III, was studied in various supraventricular arrhythmias. In total, 220 patients with atrial fibrillation (AF), atrial flutter (AFl), supraventricular tachycardia (SVT) and frequent supraventricular extrasystoles (SVE) were examined. ECG monitoring and echocardiography data, electrolyte balance and blood biochemistry were assessed. left ventricular myocardial kinetics and perfusion were studied by computed Tc-99 scintigraphy (Siemens-E. CAM camera, two detectors, 90 degree rotation, 16 gates per cardiac cycle; data analysis with 4DM sped program). Nibentan pharmacokinetics and pharmacodynamics, as well as its metabolite levels, were measured with highly effective chromatography-mass spectrometry. Nibentan was highly effective in various supraventricular arrhythmias, without affecting central hemodynamics or left ventricular perfusion. There was a positive correlation between nibentan administration time, its active metabolite detection, plasma Mg level increase, and QTinterval elongation. Conclusion: Nibentan, a new antiarrhythmic agent, is highly effective for supraventricular paroxysmal arrhythmias (AF, AFl, SVT) management. Due to long QT and ventricular tachycardia risk, nibentan should be administered at cardiac resuscitation departments or intensive care units only.

Aim. To study clinical efficacy of a new, class III, antiarrhythmic agent, nibentan, in various supraventricular (SV) cardiac arrythmias. Material and methods. In total, 153 patients with atrial fibrillation, atrial flutter, or SV tachycardia were examined. Electrocardiography monitoring, echocardiography, electrolyte balance assessment, biochemical blood assay were performed. Left ventricular (LV) kinetics and perfusion was measured by myocardial computer scintigraphy method. The results were processed with 4DM spect program. Results. Nibentan demonstrated high antiarrhythmic activity in various SV cardiac arrhythmias No significant effects on central hemodynamics and LV myocardial perfusion were observed. Conclusion. In this trial, a new medication, nibentan, demonstrated the qualities of a true class III antiarrhythmic agent.

The previouse experimental studies revealed that mezenchimal bone marrow stem cells (MSC) have the ability of differentiating into cardiomiocytes in vitro and in vivo inducting angiogenesis and restoring the impared myocardial function. At that, the cell technology capacities in clinical cardiology remain unstudied.Starting from January 2003 8 patients suffering from heart failure underwent the transplantation of autological MSC with different stages of cultivation: MSC was administered intracoronary to 6 and intramuraly to the post-infarction cardiosclerosis zone. In three cases the MSC were marked with thallium-20 Idirectly before transplantation in order to define the location of MSC during the hours after transplantation. The results of radionuclide scintigraphy demonstrated that in 1, 5 hours after intracoronary administration and in 6, 5 hours after intramyocardial injection MSC remain in the zone of administration. In 1 month after the transplantation the improvement of regional perfusion and diastolic function was observed in old patients. Significant growth of functional ischemia of the left ventricle from 31 to 40 % was observed in patient suffering from ИКМП after intramural administration of MSC. In 1 month after MSC transplantation quality of life and phisical stress tolerance improvement was observed. Intracoronary administered MSC remain in coronary artery, through which MSC was administered. Intracoronary and intramural administration of MSC improves functional indices of retractive myocardial function, increases physical stress tolerance and life quality of patients suffering from chronic heart failure.